发明名称 INDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
摘要 The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.
申请公布号 US2017057925(A1) 申请公布日期 2017.03.02
申请号 US201615239348 申请日期 2016.08.17
申请人 Janssen Pharmaceutica NV 发明人 Macielag Mark J.;Zhang Rui;Parker Michael H.;DeCorte Bart L.;Greco Michael N.
分类号 C07D231/56;C07D401/14;C07D405/14;C07D409/14;C07D401/04;C07D417/14 主分类号 C07D231/56
代理机构 代理人
主权项 1. A compound of formula (I) wherein R0 is selected from the group consisting of hydrogen and hydroxy;is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl, thienyl, pyridyl, thiazolyl, benzothiazolyl and benzo[d][1,3]dioxolyl, wherein the phenyl, furyl, thienyl, pyridyl, thiazolyl, benzothiazolyl or benzo[d][1,3]dioxolyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, 4alkyl, fluorinated C1-4alkyl, C1-4alkoxy, fluorinated C1-4alkoxy, cyano, —C(O)OH, C(O)O—C1-4alkyl, —C(O)NRARB and NRARB; wherein RA and RB are each independently selected from the group consisting of hydrogen, C1-4alkyl, hydroxy substituted C1-2alkyl and carboxy substituted C1-2alkyl, provided that each substituent is bound to a carbon atom of the ring;is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, furyl, thienyl, pyridyl, thiazolyl, benzothiazolyl and benzo[d][1,3]dioxolyl, wherein the phenyl, furyl, thienyl, pyridyl, thiazolyl, benzothiazolyl or benzo[d][1,3]dioxolyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C1-4alkyl, fluorinated C1-4alkyl, C1-4alkoxy, fluorinated C1-4alkoxy, cyano, —C(O)OH, C(O)O—C1-4alkyl, —C(O)NRCRD and NRCRD, wherein RC and RD are each independently selected from the group consisting of hydrogen, C1-4alkyl, hydroxy substituted C1-2alkyl and carboxy substituted C1-2alkyl, provided that each substituent is bound to a carbon atom of the ring;is selected from the group consisting of (a)wherein R1 is selected from the group consisting of hydrogen, C1-4alkyl, hydroxy substituted C1-4alkyl, —C(O)—(C1-4alkyl), —(C1-2alkyl)-C(O)OH, —(C1-2alkyl)-C(O)—O—(C1-4alkyl), —(C1-2alkyl)-O—(C1-2alkyl)-C(O)OH, —(C1-2alkyl)-C(O)—NRERF, —SO2-(fluorinated C3-6cycloalkyl and benzyl; wherein the benzyl is optionally substituted with one substituent selected from the group consisting of —C(O)OH, —C(O)O—(C1-4alkyl) and —C(O)—NRERF, and wherein RE and RF are each independently selected from the group consisting of hydrogen and C1-2alkyl, and (b)wherein R2 is selected from the group consisting of C3-6cycloalkyl and C1-4alkyl, a is an integer from 0 to 1; b is an integer from 0 to 1; c is an integer from 0 to 1; X is selected from the group consisting of CH and N; provided that when one or both of b or c is 0, then X is CH; such thatis selected from the group consisting of piperazin-1,4-diyl, piperidin-1,4-diyl, pyrroldin-1,3-diyl and azetidin-1,3-diyl, R3 is selected from the group consisting of C1-4alkyl, halogenated C1-4alkyl, —C(O)-(fluorinated C1-2alkyl), —C(O)-(hydroxy substituted C1-4alkyl), —C(O)—(C1-2alkyl)-C(O)OH, —C(O)—(C1-2alkyl)-C(O)O—(C1-4alkyl), —C(O)—(C1-4alkyl)-C(O)—NRGRH, —C(O)O—(C1-4alkyl), —C(O)O—(C3-6cycloalkyl), —C(O)—NRGRH, —SO2—(C1-4alkyl), —SO2-(halogenated C1-4alkyl), —SO2—(C1-2alkyl)-C(O)OH, —SO2—(C1-2alkyl)-C(O)O—(C1-4alkyl), —SO2—NRGRH, —SO2—(C1-2alkyl)-C(O)—NRGRH, phenyl, pyridyl (provided that the pyridyl is bound through a carbon atom) and -L1-R4; wherein phenyl or pyridyl is optionally substituted with one or more (preferably one to two) substituents independently selected from the group consisting of halogen, C1-4alkyl, halogenated C1-2alkyl, C1-4alkoxy, —(C1-2alkyl)-C(O)OH, —(C1-2alkyl)-C(O)O—(C1-4alkyl), —(C1-2alkyl)-C(O)—NRJRK, —O—(C1-2alkyl)-C(O)OH, —O—(C1-2alkyl)-C(O)O—(C1-4alkyl), —O—(C1-2alkyl)-C(O)—NRJRK, —C(O)OH, —C(O)O—(C1-4alkyl) and —C(O)—NRJRK, wherein RG and RH are each independently selected from the group consisting of hydrogen and C1-4alkyl, and wherein RJ and RK are each independently selected from the group consisting of hydrogen and C1-2alkyl, L1 is selected from the group consisting of —CH2—, CH2CH2—, —CH(CH3)—, —C(O)—, —C(O)—CH2—, —C(O)O—, —C(O)O—CH2—, —C(O)—NH—, —C(O)—NH—CH2— and —SO2—; R4 is selected from the group consisting of C3-6cycloalkyl, phenyl, furanyl, thienyl, pyridyl, pyrazolyl, triazolyl, and tetrazolyl; wherein the phenyl, furanyl, thienyl, pyridyl, pyrazolyl and triazolyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, C1-4alkyl, halogenated C1-4alkyl, C1-4alkoxy, halogenated C1-4alkoxy, —C(O)OH, —C(O)O—(C1-4alkyl), NRLRM and —SO2—NRLRM, wherein RL and RM are each independently selected from the group consisting of hydrogen and C1-2alkyl, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
地址 Beerse BE